Hexarelin and EP-80317 suppress CALU-1 lung carcinoma cell growth via non-GHS-R1a receptor
Background
Non-small-cell lung carcinoma remains a major unmet therapeutic need, with limited molecular targets beyond standard chemotherapy. Growth hormone secretagogues (GHS) were developed to stimulate GH release via the GHS-R1a receptor, but evidence suggests peptidyl GHS may exert direct antiproliferative effects in tumor tissue independent of GH axis activation. A key gap existed around whether nonendocrine lung carcinomas express a distinct binding site for peptidyl GHS — separate from the canonical GHS-R1a — and whether such binding translates into functional growth inhibition. EP-80317, an hexarelin analog engineered to be devoid of GH-releasing activity in vivo, offered a tool to dissect receptor-mediated tumor effects from systemic endocrine actions.
Study Design
Binding studies used [125I]Tyr-Ala-hexarelin as a radiolabeled tracer applied to membranes from nontumoral human lung, endocrine lung neoplasms, nonendocrine lung carcinomas, and the CALU-1 human lung carcinoma cell line. Displacement assays tested peptidyl GHS (GHRP-6, hexarelin, EP-80317) versus nonpeptidyl GHS (MK-0677) and the endogenous ligand ghrelin. GHS-R1a mRNA expression was assessed across all tissue types. Functional endpoints in CALU-1 cells were IGF-II-stimulated [3H]thymidine incorporation (DNA synthesis) and cell growth, evaluated dose-dependently for hexarelin, EP-80317, ghrelin, and MK-0677.
Results
[125I]Tyr-Ala-hexarelin binding was markedly higher in nonendocrine lung carcinomas than in either normal lung tissue or endocrine lung neoplasms. Peptidyl GHS — GHRP-6, hexarelin, and EP-80317 — effectively displaced tracer binding to tumor membranes, while MK-0677 and ghrelin produced no competition, indicating a receptor pharmacology distinct from the canonical GHS-R1a. GHS-R1a mRNA was detected in 50% of endocrine lung tumors but was absent in all nonendocrine neoplastic tissues and in CALU-1 cells, confirming the binding site is not GHS-R1a. In CALU-1 cells, hexarelin and EP-80317 caused dose-dependent inhibition of IGF-II-stimulated thymidine incorporation and cell growth at concentrations close to their measured binding affinities; ghrelin and MK-0677 were inactive.
The single most striking result: EP-80317 — an hexarelin analog with no GH-releasing activity in vivo — matched hexarelin in antiproliferative potency in CALU-1 cells, functionally decoupling tumor growth inhibition from systemic GH-axis activation.
Key Findings
- [125I]Tyr-Ala-hexarelin binding was greatest in nonendocrine lung carcinomas vs. normal lung or endocrine tumors
- GHS-R1a mRNA detected in 50% of endocrine lung tumors; absent in CALU-1 and all nonendocrine tissues
- GHRP-6, hexarelin, and EP-80317 displaced radiolabeled tracer; MK-0677 and ghrelin did not compete
- Hexarelin and EP-80317 dose-dependently inhibited IGF-II-stimulated thymidine incorporation in CALU-1 cells
- EP-80317, devoid of GH-releasing activity in vivo, matched hexarelin antiproliferative potency in CALU-1
Why It Matters
Peptidyl GHS compounds like hexarelin may carry direct anticancer activity in lung carcinoma independent of their GH-releasing function, a mechanistic split with major implications for therapeutic development and for interpreting effects in users stacking these peptides. The existence of a non-GHS-R1a receptor selectively expressed in nonendocrine lung tumors opens a novel molecular target untouched by nonpeptidyl agents like MK-0677. Clinically, translation is early — this is in vitro cell-line data — but the findings justify receptor-characterization studies and in vivo tumor models. For protocol designers, the data imply that MK-677 cannot substitute for hexarelin in any putative antiproliferative application, as the two compound classes act on entirely different receptors in lung carcinoma tissue.
